Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Universidade de São Paulo
2011
|
| Subjects: | |
| Online Access: | https://www.redalyc.org/articulo.oa?id=67240194022 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Long-term health benefi ts of appetite suppressants remain unproven Francisco José Roma Paumgartten Salud Anti Long Weight Obesity loss drugs Because of the increasing prevalence of obesity, prevention and treatment of overweight has become a major public health concern. In addition to diet and exercise, drugs are needed for patients who failed to lose weight with behavioral treatment. The current article aimed to summarize recent concerns on the safety and effi cacy of appetite suppressants. Several appetite suppressants have been banned for safety reasons. In 2010, sibutramine was withdrawn from the market because a long-term study showed it increased the risks of cardiovascular events. So far no study with a suffi ciently large sample size has demonstrated that appetite suppressants can reduce morbidity and mortality associated with overweight. The withdrawal of sibutramine highlights that guidelines for the evaluation of weight control drugs must be more stringent, and studies on their long-term health benefi ts are needed prior to their marketing. 2011 artículo científico 0034-8910 https://www.redalyc.org/articulo.oa?id=67240194022 en http://www.redalyc.org/revista.oa?id=672 Revista de Saúde Pública application/pdf Universidade de São Paulo Revista de Saúde Pública (Brasil) Num.6 Vol.45